HPP 737Alternative Names: HPP737
Latest Information Update: 20 Jan 2016
At a glance
- Originator vTv Therapeutics LLC
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 20 Jan 2016 Phase-I clinical trials in Inflammation in USA (unspecified route) before January 2016
- 19 Dec 2015 Preclinical trials in Inflammation in USA (unspecified route) before December 2015